Tesamorelin

FDA-approved Egrifta protocol: 2 mg subcutaneously once daily — one injection every evening before bed (synchronization with nighttime GH peak).

Inject into abdomen or front of thigh, rotating injection sites; avoid area around navel.

Course duration of 12 weeks provides clinically significant visceral fat reduction of 15–18%; continuation to 26 weeks — result stabilization.

Break between courses 4–6 weeks. One course per year as standard maintenance.

Mandatory IGF-1 monitoring at start, after 6 weeks and at course end. If IGF-1 above reference — dose adjustment.

Do not mix with other substances in same syringe. Store in refrigerator 2–8°C.

Tesamorelin is a specific pharmaceutical product (Egrifta). Check availability with DOZA consultant.

Before starting — mandatory specialist consultation and analysis of IGF-1, glucose, lipid profile.

Tesamorelin (brand Egrifta) — synthetic analog of natural GHRH (Growth Hormone-Releasing Hormone), consisting of 44 amino acids. The only peptide in this group approved by FDA (2010) for medical use — for reducing excess visceral (abdominal) fat in patients with HIV-associated lipodystrophy. In this patient group, clinically confirmed visceral fat reduction of 15–18% over 26 weeks and IGF-1 increase of 80–100% from baseline.

Tesamorelin specifically targets visceral fat — the most dangerous type of fat for health, surrounding internal organs and directly associated with cardiovascular disease risk, type 2 diabetes, and metabolic syndrome. Unlike exogenous growth hormone, Tesamorelin preserves natural GH pulsation and doesn't suppress pituitary production.

In studies, Tesamorelin showed potential in visceral fat reduction (15–18% over 26 weeks), improved metabolic markers (triglycerides, insulin sensitivity), increased IGF-1 levels, potential in cognitive functions in HIV patients, and prospects for non-alcoholic fatty liver disease (NAFLD/NASH).

Attention: Tesamorelin is a specific pharmaceutical product (Egrifta by Theratechnologies). Unlike DOZA's main range, it's not available in pre-mixed pen Pen Peptide format. Availability — upon inquiry; cost and protocol are individually coordinated with DOZA consultant.

Tesamorelin (Egrifta) — stabilized synthetic analog of GHRH (growth hormone-releasing hormone), 44 amino acids. The only FDA-approved peptide in this group (2010). Binds to GHRH receptor in somatotrophs of anterior pituitary, stimulating natural pulsatile GH release (unlike exogenous GH, preserves physiological pulsation). Elevated GH activates IGF-1 production in liver by 80-100% from baseline (Falutz et al., NEJM 2007). IGF-1 stimulates visceral fat lipolysis through hormone-sensitive lipase activation in adipocytes — selectively acts on abdominal fat, minimally on subcutaneous. Clinical study LIPO-2009 (phase III, n=816): visceral fat reduction of 15-18% over 26 weeks, improved triglycerides and insulin sensitivity. Additional potential: studies in NAFLD/NASH (fatty liver disease — Stanley et al., Lancet HIV 2014) and cognitive impairment.